DTC Ads Should Be Better, Not Banned, In Wake Of Vioxx, Ex-FDAer Pitts Says
The response to the Vioxx withdrawal offers further evidence of the need for FDA and manufacturers to modify the "brief summary" requirement in direct-to-consumer ads, former Associate Commissioner for External Relations Peter Pitts said during a Nov. 10 Drug & Device Dialogue audio conference sponsored by F-D-C Reports and Polidais LLC